Adding atezolizumab to chemotherapy significantly prolongs progression-free survival in the first-line advanced urothelial cancer setting, according to the IMvigor130 trial results presented at the ESMO Congress 2019.

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

Abhishek Srivastava and Neal Shore survey upcoming trials and promising new immunotherapies for advanced PCa, while highlighting some of the successes in PCa immunotherapy.

The development of immune-related adverse events is associated with improved clinical outcomes in response to immune checkpoint blockade in patients with small-cell lung cancer, suggests a chart review.

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Read more on this CAR T-cell therapy announcement here

Autologous CD19-directed chimeric antigen receptor T-cell therapy leads to high remission rates and durable responses in children, young adults, and adults with refractory acute lymphoblastic leukemia, indicate two reports appearing in The New England Journal of Medicine .

Read more on this decision affecting treatment of some types of large B-cell lymphoma here

The results of two studies published in The New England Journal of Medicine support the use of autologous chimeric antigen receptor T cells directed against CD19 in patients with relapsed or refractory B-cell lymphomas.

Patients at high risk for severe neurotoxicity after CD19-targeted chimeric antigen receptor–modified T cell infusion can be identified using a predictive algorithm, indicates a report.

Summary of Science Translational Medicine article covered in: Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma

The chimeric antigen receptor (CAR) T-cell immunotherapy uses autologous T cells that are genetically modified to include a CAR protein that can identify and remove cells expressing CD19.

Treatment with autologous chimeric antigen receptor T cells directed against the epidermal growth factor receptor variant III mutation is feasible and well tolerated in patients with recurrent glioblastoma, indicates a first-in-human study. Read the linked expert summary by Michael Weller.